Discontinued drugs in 2008: oncology drugs

被引:18
|
作者
Williams, Robert [1 ]
机构
[1] Canc Res UK, Drug Dev Off, London WC2A 3PX, England
关键词
1D09C3; 4-demethylpenclomedine; ARQ-171; AZD-4992; CNF-1010; DN-101; FCE-28068; FCE-28069; folitixorin calcium; huMy9-6-DM4; INNO-305; mitumprotimut-T; MLN-8054; N-acetylcysteine; PD-0325901; phosphomannopentaose sulfate; PI-166; SGX-523; spisulosine; Symadex; tozasertib lactate; varalanib; zanolimumab; ATTRITION RATES;
D O I
10.1517/13543780903151806
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The failure of drug candidates in clinical development remains a critical issue for the pharmaceutical and biotechnology industries. This article documents those oncology drugs discontinued in 2008 and briefly reviews reasons for termination of development. Source information was derived from a search of the Pharmaprojects database for drugs reaching phase I - III clinical trials.
引用
收藏
页码:1581 / 1594
页数:14
相关论文
共 50 条